Highlights on Cerebral Arteriovenous Malformation Treatment Using Combined Embolization and Stereotactic Radiosurgery: Why Outcomes are Controversial?

Faustina N A. Sackey 1, Nathaneal R. Pinsker 2, Benjamin N. Baako 3

1. Loeb Health Research Institute at Ottawa Hospital, University of Ottawa, Ontario, Canada  2. Internal Medicine, Kings College Hospital  3. Surgery, University of Ghana School of Medicine and Dentistry

Corresponding author: Faustina N A. Sackey, faustinas2004@yahoo.com

Abstract

Cerebral arteriovenous malformations (AVMs) are abnormal tangling between brain arteries and veins causing an arteriovenous shunt called nidus with an intervening network of vessels from the region of formation and spans through the brain. AVM effect is debilitating to the affected individual due to associated persistent intracerebral hemorrhage, resulting in significant occurrences of seizures and neurological damage. Recent innovative treatments involve a combination of embolization (Embo) procedures followed by stereotactic radiosurgery (SRS), designed to optimize less-invasive practice for the obliteration of the AVMs. Three groups of investigators reported different outcomes based on obliteration rates and adverse events, making the effectiveness of options for therapy, controversial. We have taken the case-oriented-approach to highlight on varying outcomes from various studies and provide insights as to why findings from different operation settings could be so conflicting.

We chose 18 articles for systematic analysis based on initial electronic database selection of 40 key papers already identified for inclusion, followed by independent blinding assessment by two co-authors. Our evaluation was based first on our specific inclusion criteria, examining method quality, obliteration rates, serious adverse events (SAEs) and mortality rates. Second, we made a comparison between SRS or embo alone treatments versus combined embo/SRS procedures, relative to AVM sizes, following Spetzler-Martin (SM) method. Third, we considered publications which had concrete statistics with well-defined P-values and clarified outcomes for accurate evaluation.

We found that patients with small to medium-sized AVM were susceptible to either embo alone or SRS alone treatments, yielding obliteration rates from 71%-100%. Except for one report, giant sizes AVMs were not amenable to these single treatments, subjecting patients to embo/SRS procedures, which yielded mixed results: One group reported 52%-65% obliteration rates, compared to 25%-28% embo alone treatment. A second group contradicted this apparent beneficial outcome, obtaining obliteration rates of 53% with combined treatment compared to 71% with SRS alone, four-year postoperative. A third group reported there was no difference between single and combined treatments and obtained complete obliteration of 70%-82%, ranging from three-five-years postoperative follow-up. In all the cases analyzed, obliteration rates improved with time. SAEs, such as persistent hemorrhage and permanent neurologic deficits (P-NDs), as well as mortality, were minimal during intraoperative and postoperative follow-ups.

The problem of conflicting outcomes in combined treatments of AVM by EMBO/SRS exists. Previous investigators, however, have overlooked to address this issue satisfactorily. Our analysis found that the reported inconsistencies in AVM treatment outcomes are attributable to key factors making therapy unpredictable, which includes: the size of the AVM, nidus localization and accessibility of either Embo or radiation dose applied, certain Embo materials lowering obliteration rates by masking radioactive effect on the nidus during SRS and follow-up timing for obtaining obliteration rates determine the extent of obliteration.

We have indicated critical factors which require consideration when planning strategies for treatment of AVM patients and have made suggestions of how to overcome such hurdles.

Introduction And Background

Cerebral arteriovenous malformations (AVMs) are irregular connections of the brain capillary network [1-3]. Typically, AVMs localize in the cerebral hemisphere as cone-shaped lacerations with the apex of the cone approaching the ventricles [3-4]. According to the American Heart Association, cerebral AVM is a disorder
which occurs in approximately two to five in 1,000 individuals in a general population, and it is more common in males than females [3-4]. Diagnosis is prevalent in the third decade (30 years) of life during which intracranial hemorrhage or seizure is frequent [3-4]. About 50% of the hemorrhagic cases results in 55%-81% morbidity and 10-30% mortality [3-4].

The etiology of AVM formation is not clear; nonetheless, it has been postulated that genetic factors involving gene alterations with subsequent overexpression or hyperactivity of blood flow hemodynamic regulatory elements, as well as, vascular endothelial growth factor (VEGF-A) signaling [1] might play roles. Additionally, epigenetic factors might act by modifying the activity of vascular controlling genes via deoxyribonucleic acid (DNA) methylation [5]. The consequences of these alterations are enhanced and progressive vascular drainage malformation, which leads to frequent hemorrhage encountered by patients are affected by brain AVMs. Recent endeavors to map the molecular basis of the underlying cause of the disorder are gene linkage and genetic mutation analysis of the defective hemodynamic controlling factors [6].

Although AVM development can occur anywhere in the body, cerebral AVMs tend to be most debilitating, especially, if they reside in eloquent brain regions which are parts of the brain controlling speech, mobility and senses. AVMs in eloquent locations can rupture easily and cause intracranial hemorrhage, thus, presenting symptoms such as seizures, stroke, impaired speech, and vision, broadly classified as neurological deficits [7-9]. Other notable symptoms are paralysis, loss of coordination, mental disorder, memory depredation (dementia), hypoxia, severe headache, feeling of numbness and dizziness [7-9]. Therefore, the cause of treatment is to alleviate the risk of high-pressure blood flow through these malformed vessels to prevent vessel rupture and improve or preserve neurological function.

AVM is diagnosed by the use of computed tomography (CT) scan, magnetic resonance imaging (MRI) and cerebral angiography which involves X-radiation (x-ray) imaging, following contrast injection [9-11]. Briefly, the dye is injected into a catheter inserted in the patients’ femoral artery which then travels through the neck internal carotid artery to the brain. Pictures are taken to reveal the localized position of the AVM. These imaging tests are important in that, apart from showing the location of the AVM, they can be used to identify the original size, change in size after treatment, and whether the AVM had been bleeding or unruptured. Typically, estimation of the AVM nidus is carried out by using a scoring method called Spetzler-Martin (SM) grading scale [12], which helps in predicting the risk of surgical mortality and serious adverse effects (SAEs). SM grading scale puts into consideration; a) nidus size and b) eloquent localization of the AVM, that is, the parts of the brain that control speech, motor functions, and senses known as the brain cortex. The latter includes the brainstem, thalamus, hypothalamus and the connection between the cerebellum and the brain stem called cerebellar peduncles, as well as, visible and language regions, and c) the existence of deep venous drainage. Nidus sizes less than three cm, three-six cm, and less than six cm are scored one, two and three points, respectively. AVM in the eloquent region is scored one point, while the existence of deep vein drainage scores one point. Thus, a patient with AVM total scores of six points has a prognosis that scores all the points that ultimately lead to SAEs and thus is predicted to be at most mortality risk on surgical outcome. Health conditions may also play roles in determining surgical outcomes even of patients with lower SM grading scores [13]. We reviewed a set of articles to address controversies in reported outcomes, the probable causes and suggested cautionary notes for remedy towards successful treatment outcomes.

**Review**

**Search strategy and articles selection**

Between December 2015-2016, we searched the medical literature analysis and retrieval system online (MEDLINE) database via PubMed, Excerpta Medica database (Embase) Database-Ovid, and Elton B. Stephens Co. (EBSCO’s) Medical Database for brain atrioventricular malformations and intracranial AVMs ranging from 1995 to 2016. We supplemented our searches with Google search engine on the same topic. The keywords used were as follows: brain AVMs, radiosurgical treatments, stereotactic radiosurgery (SRS), embolization (embo), combined embo/SRS, small AVMs, large AVMs, treatment outcomes.

We obtained a total of 40 abstracts from the searches, out of which we chose 30 relevant full-text articles. Two reviewers who mutually agreed on inclusion/exclusion selection criteria screened the reports. Co-author one selected 20 articles (first set). Co-author two blinded to the first co-author, evaluated the 30 papers independently, screened and also selected 20 articles (second set). The two co-authors held a mutual consent meeting and selected 18 articles which appeared in both sets of selections to be included in the study and resolved any discrepancies to avoid observer bias in articles selection.

**Study selection**

_Inclusion Criteria:_ Our inclusion criteria considered the following: 1) In-depth description of AVM surgery methodology. 2) Large patient population size (>20,000). 3) Single SRS and combined embo/SRS treatments and outcomes. 3) AVM sizes and grouping by SM grading. 4) Serious adverse events (SAEs). 5) Obliteration rates. 6) Comparable statistical analysis. 7) How often the authors’ published in the field (to ensure that treatment strategies and methods had been refined by experienced investigators for data
has been the profound treatment choice with significantly high obliteration rates (mean, 50%-68%) for AVM sizes (SM I, II and at times, III), microsurgical resection, also known as stereotactic radiosurgery (SRS), carry more weight than treatment, and a decision could be made to leave the nidus untouched. For smaller AVMs, for example, if the volume of a patient nidus is SM V-VI and localized in eloquent regions, the risk of SAEs will be made possible is dependent on the AVM size, it’s possible location, patient age, and health history. For measurements, AVM sizes were determined using the Spetzler-Martin (SM) grading method to test for variable continuity and frequency categorization.

Techniques used previously in determining obliteration rates and serious adverse events in the articles evaluated

The AVM treatment techniques involve passing a tiny catheter into the cerebral vessels feeding it until it reaches the nidus [9]. Embolization material is then injected to occlude most of the AVM to make subsequent stereotactic radiosurgery (SRS) removal feasible and safer by reducing operation time associated with blood loss during the resection of the lesions [13-14]. SRS procedure entails passing a beam of radiation to target the lesion. Over approximately two-three years of patient follow-up routines, it is possible to track the time course of obliteration of the AVM nidus. Outcomes were analyzed by comparison of digital subtraction angiographies (DSA) before and after treatment, as well as, clinical presentation results [15-20]. Briefly, obliteration rates were measured by obtaining ratios between the original nidus size and follow-up periods after treatments, and also, morphology evaluation of restricted venous outflow. Seizures were measured by angiography results of venous drainage patterns. The extent of hemorrhage was measured by determining velocity and volume flow rate (VFR) by angiography.

Statistical methods typically used to quantify outcomes are univariate (T-test, chi-square, Fisher’s exact test) and multivariate Cox-regression or logistic analyses [9,14,7], the use of the log-rank test [13] in risk factor determination characterized by obliteration, hemorrhage, radiation-induced changes and post radiosurgery adverse events [8,14-19]. Obliteration rates are also determined using Kaplan-Meier analysis. Comparison between study groups is made using Fisher exact, chi-square or Mann–Whitney–Wilcoxon test [8,14-19], having a P-value < 0.05 indicating statistical significance. Flickinger Pollock scale [20-21] is used to test for variable continuity and frequency categorization.

AVM treatment procedures employed in the articles evaluated

AVMs sizes were determined using the Spetzler-Martin (SM) grading method [12] or by volume measurements [22] after DSA, before making a decision on treatment strategy. Whether or not treatment can be made possible is dependent on the AVM size, it’s possible location, patient age, and health history. For example, if the volume of a patient nidus is SM V-VI and localized in eloquent regions, the risk of SAEs will carry more weight than treatment, and a decision could be made to leave the nidus untouched. For smaller AVM sizes (SM I, II and at times, III), microsurgical resection, also known as stereotactic radiosurgery (SRS), has been the profound treatment choice with significantly high obliteration rates (mean, 50%-68%) [15-19].
Certain investigators have also reported the use of embolizers such as Polyvinyl alcohol (PVA), n-butyl cyanoacrylate (nBCA), recently, Glubran 2 and Onyx [23], which all tend to shrink the AVM, curing low percentage of patients, but in the majority of cases, low obliteration rate have been the outcome for embolization (Embo) alone treatment. Contrary to promising results for single micro or radiosurgical procedures, patient treatment has been more challenging with AVMs which have SM grading sizes >III-VI [14,24-25]. Because of their large size, the AVMs are tough to uproot by single SRS procedure, and repetitive SRS sessions always produced disabling outcomes, compared to single operations [26]. Hence, the adopted strategy is to utilize a combined multidisciplinary therapy of initial embo procedure to reduce the size of the nidus [9, 14-18] before SRS, using gamma knife (GK) [14,25-29], or Linear Accelerator (LINAC) [27-28]. Embo also minimizes SRS-related complications in the majority of cases [9, 14-17,22-25]. Therefore, it has become an adjunctive tool used before SRS procedures for treatment of large masses. The aim is to eradicate the AVMs with high efficacy while maintaining healthy tissue surrounding the mass. Unfortunately, using combined embo/SRSg for treatment and management of AVMs have yielded different outcomes and thus remain controversial [14-17, 30-33, 34-36]. To address the reasons behind these differences, a set of articles were selected and analyzed, as discussed below.

### AVM size and timing play roles in controversial outcomes according to most reported cases

Betramello, et al. [29] reported 255 out of 277 patients with cerebral AVMs treated cases over a five-year period (2000-2004) in the neurological facility. Ninety-eight underwent combined embolization with polybutyl cyanoacrylate (PBCA), Glubran two, Onyx or Glubran two/Onyx, and a single GK treatment; 16 patients went through embolization alone treatment, while 113 had single SRS treatment because of their small nidus size (results not reported). Out of the 98 patients that underwent combined treatment, 44 completed the follow-up routine. The clinical parameters measured included hemorrhage, epilepsy, focal neurological defects and cognitive impairment. Shown in Table 1 is a summary of the results [29].

| Characteristics                        | Combined Treatment (Embo + SRS) | Single Treatment (Embo) |
|----------------------------------------|---------------------------------|-------------------------|
| Number                                 | 44                              | 16                      |
| Total obliteration                     | 23 (52.3%)                      | 4 (25.0%)               |
| Hemorrhage                             | 14 (31.8%)                      | 2 (12.5%)               |
| Epilepsy                               | 16 (36.4%)                      | 1 (6.25%)               |
| Focal deficit                          | 2 (4.5%)                        | 1 (6.25%)               |
| Technical complications (glued catheter)| 4 (9%)                          | 0                       |
| Mortality                              | 0                               | 0                       |
| Non-eloquent nidus location            | 18 (40.9%)                      | 2 (12.5%)               |
| Eloquent nidus location                |                                 |                         |
| Nidus volume <10 cm³                   | 22 (50%)                        | 2 (12.5%)               |
| Nidus volume 10-20 cm³                 | 19 (44%)                        | 4 (25%)                 |
| Nidus volume >20 cm³                   | 15 (34.1%)                      | 0                       |
|                                        | 6 (13.6%)                       | 0                       |

**TABLE 1: Summary of outcomes of arteriovenous malformations (AVM) patients treated with single embolization (embo) or combined embo/stereotactic radiosurgery (SRS)**

As shown in the Betramello, et al. study [29], the purpose of the combined treatment was to be able to treat AVMs with gigantic SM grades. The results precisely showed the combined treatment worked better with respect to reducing the size of the AVM (52.3% obliteration rate), compared to the embolization treatment alone (25%). There were more temporal SAEs with the combined treatment, but this could have been attributable to the aggressive nature of the treatment. The single SRS treatment outcomes were not shown to allow comparison. Shown in Figure 1 is an interesting observation; the DSA images revealed before (Figure 1A) and after administering a single Onyx treatment to a 60-year-old male with nine cm³ AVM size. He experienced an instant complete obliteration (Figure 1B). In a like manner, a 42-year-old male with a much larger AVM size of 22 cm³ before treatment (Figure 1C), also displayed the same obliteration outcome, but over a much longer period. Despite the time factor involved, he had five successive embolization procedures.
procedures followed by a single SRS. Further, he went through a follow-up period of three years (Figure 1D).

**FIGURE 1**: Angiography images showing changes in arteriovenous malformations (AVM) obliteration rates before and after combined treatment over a time

(A) Small arteriovenous malformations (AVM) size obtained before treatment and (B) immediately after Onyx embolization with massive AVM size (C) taken before treatment, and (D) after three years follow-up after combined embolization/SRS treatment. (AB) Pre-rolandic digital subtraction angiography (DSA) of a 60-years-old male with nine cm$^3$ AVM volume, presented with aplasia. Images were taken before (A) and immediately after Onyx embolization (B), showing complete obliteration of the AVM nidus. (CD) Right rolandic DSA images from a 42-years-old male with 22 cm$^3$ AVM volume, presented with a partial seizure. Before treatment (C) and three-year follow-up after combined treatment with Onyx/SRS (D), also showing complete obliteration of the AVM nidus. White arrows indicate the position of the AVM. Figure reproduced from Betramello, et al. [29]

The results suggest that achievement of an effective obliteration with a much larger AVM requires stepwise sessions, aggressiveness, and time-effective treatments. Thus, investigators need to consider these factors as contributing to an overall consistent outcome when grouping patients in a study. Similarly, Ding, et al. [15] reported obliteration rates obtained from 72 patients diagnosed with AVM by MRI or DSA. These patients (44.5%) had at least AVM sizes not less than SM III. They underwent single SRS with 20 Gy dose and follow-up monitored by determination of obliteration rates obtained by data analysis from series of DSA images and plotting a graph from the results, as shown in Figure 2A. This plot parallels with obliteration time course obtained by another group, Dalyai, et al. [14] in figure 2B, who instead of a single SRS treatment, performed a combined N-butyl cyanoacrylate (nBCA) embolization and 21 Gy gamma knife surgery (GKS) procedures in 95 patients of which 47% had large AVM, SM IV-SM V.
Figure 2: Plots showing obliteration rates of AVM, versus time, after single stereotactic radiosurgery (SRS) or combined embolization/SRS treatments

(A) Time course of cumulation of obliteration rate obtained from 444 patients with AVM largely of Spetzler-Martin (SM) III-IV sizes who underwent 20 Gy SRS alone treatment with 20 years follow-up period. (B) A parallel comparative graph from a study by another group but with 95 patients with approximately 50% of the group presented with giant size AVMs (SM IV-V) in eloquent regions who underwent a combined therapy sessions of Onyx embolization and SRS treatments with 15 years follow-up period. Figures reproduced from Ding, et al. [15] and Dalyai, et al. [14]

In contrast to the graph obtained by Ding and his group, obliteration rate in the latter was obviously slower and appeared to be reaching its peak with approximately 52% rate around the fifth year (Graph B). Graph A, on the other hand, went through a second phase after the seventh year and the obliteration rate reached about 95% by 18 years. It seems from this analysis that the single SRS treatment has resulted in a better obliteration outcome than the combined treatment. The inference likely to be made from these two reports is that the SM sizes of the AVMs in both studies vary and so the comparison is being drawn between small sizes AVM in (Figure 2A) and large complex AVM sizes (Figure 2B) and that the latter had imposed limitations on the obliteration outcome. Large AVM sizes once more reflect on the requirements for more aggressive treatments such as stepwise embolization sessions, increasing the linear accelerator (LINAC) or the gamma knife (GK) radiation dosage, as well as a requirement for much longer follow-up period to achieve significant or complete obliteration.

The obliteration rates obtained by Dalyai and co-workers were lower than those reported by other investigators, which also reflects the large AVM sizes among 47% of their patients (SM IV-V) and the initial mean volumes, which was 22 cm³. These are obviously very complex and gigantic malformations. Thus the purpose for embolization with nBCA before SRS was to generate a combination of effects for an aggressive treatment which produced 63% obliteration rate by 10 years (Table 2) [14].

| Characteristics                  | 1-3 years | 5 years | 7 years | 10 years |
|----------------------------------|-----------|---------|---------|----------|
| Total obliteration rate          | 40%       | 45%     | 56%     | 63%      |
| Hemorrhage                       | 26 (27%) of 95 patients |
| Procedure complications          | 14 (13.3%) patients out of 95 |
| Minor neurologic deficits (ND)   | 13 (12.4%) patients out of 95 |

Table 2: Summary of outcomes of AVM patients treated with combined embolization/stereotactic radiosurgery (embo/SRS) over a 10-year follow-up period

This together with the reasonable adverse events (AE) reported, the outcomes they obtained are comparable to those reported by other investigators. Karlsson, et al. obtained similar results in 2007 [18]; they used controlled doses of nBCA to embolize 18 patients with large AVM before radiosurgery and achieved 68% obliteration rate. Additionally, Gobin, et al. in 1996 [25] treated 125 patients harboring massive AVM
volumes, the majority of them ranged from SM-III-VI. The combined treatment strategy was to use nBCA to perform embolization before radiosurgery by GK. Their embolization results showed 11.2% total occlusion cases, 76% reduction in AVM sizes, making them small enough to favor radiosurgery. Subsequently, they reported outcomes of 59% (53 out of 90 patients) obliteration rate, 12.8% morbidity, 1.6% mortality, and three percent hemorrhage. The operation was performed successfully with revascularization occurring in only 11.8% of the total number of patients within a year. Therefore, Dalyai and co-workers concluded that this combined approach is very useful for the treatment of large and complex AVMs [14]. Several investigators have also obtained improved obliteration outcomes with combined treatment, ranging between 50%-78% with minimal SAEs [17,25,37-39], as displayed in Table 4.

Timing after AVM treatment is critical in determining outcome

In the Pierot, et al. report of 2013 [17], they performed series of Onyx sessions, followed by combined Onyx-SRS treatment of the residual nidus, on 20 AVM patients between 2003 and 2008. The AVMs ranged from five patients with SM I-II, 10 with SM III-IV and five patients with SM V, with a follow-up period of two-five years. By five years, 17 patients remained; five out of seven with SM I-II attained 71.4 % complete obliteration, five out of 10 with SM III-IV reached 50%. The cumulative obliteration rate recorded was 58.8% with minimal adverse effects of five percent. One interesting result showed by these authors was the revelation of gradual reduction of the size of the nidus of a patient over a time course. Figure 3 shows the left internal carotid DSA before (Figure 3A) and after treatments (Figures 3C-3D).

*FIGURE 3: Angiograms showing the time course of nidus obliteration rate in AVM patient from zero to five years*

Onyx treatment sessions were performed for four years and combined Onyx/stereotactic radiosurgery (SRS) treatment occurred in the fifth year. Selected panels from Pierot and his co-workers study, the left internal carotid digital subtractive angiograms (DSA) shows the time course of nidus obliteration of AVM patient, before treatment (A) after two years of two Onyx treatment sessions (B). Four years after treatment sessions showing only residual nidus (C) and five years after having a combined fifth Onyx session and SRS (D). Complete obliteration of the nidus occurred. White arrows indicate the position of the nidus. Figure reproduced from Pierot, et al. [17]

By the second year, about half of the nidus had obliterated (Figure 3B); in the fourth year, there was still
some residual nidus (Figure 3C), complete obliteration occurred in the fifth year (Figure 3D), during which the patient underwent a fifth and final Onyx session, followed by SRS procedure. These results suggest that timing is an important factor that can influence the outcome and contribute to the controversial reports observed in various studies and that over time, more patients could have a successful recovery from this treatment strategy.

Combined AVM treatment diminishes the quality of outcomes in certain instances

In Kano, et al. 2012 paper [37], 120 AVM patients underwent two-three embolization procedures before gamma knife surgery (GKS) or had only GKS treatment. A previous history showed that 64 patients had experienced at least one previous hemorrhage. Target AVM volume ranged between 0.2-26.3 cm³, with a median of 6.6 cm³ and median SM grade of III. Radioactive dosage median was 18 Gy. There was 19 years follow-up period (1987-2006). Percent obliteration was determined by MRI imaging or angiography images with subsequent data analysis. Hemorrhage, neurological deficits due to adverse radiation effects (ARE) and other parameters assessed. Summarized in Table 3 is a comparison of results for the single versus combined treatments for two and four-year outcomes.

| Characteristics                     | Embo/SRS | SRS |
|-------------------------------------|----------|-----|
| Total obliteration rate at four years | 53%      | 71% |
| Hemorrhage rate after SRS at two years | 3.5%    | 3.4% |
| # of Symptomatic AREs                | 11        | 10  |

TABLE 3: Summary of outcomes of AVM patients treated with single stereotactic radiosurgery (SRS) or combined embolization (embo)/SRS over four-year follow-up period

The authors observed that patients with smaller AVM volumes had better success, as compared to those with large masses and that disappointingly, there was the overall reduction in the cumulative total obliteration rate with the combined treatment (53%) than single (71%). Similarly, several groups have shown a parallel trend of results [37-39]. Sirin, et al. [38] in 2006, studied outcomes in 28 patients with gigantic AVM sizes (SM IV-VI), after embo/SRS treatment and obtained obliteration rates as worse as 20%-29% over three years follow-up period. Lee, et al. in 2015 [39], studied 199 AVM patients with a subsequent four-year follow-up. The obliteration rate with combined (Onyx/SRS) treatment was 24%, and the single SRS was 40%. Koga, et al. in 2011 [30] obtained reasonable obliteration rate of 50% with 44 patients but obtained a poor casualty rate of 12%. Xu, et al. [34] carried out cohort studies on 1,988 AVM patients and attained worse obliteration results with the combined (41%) than the single SRS (59%) treatments. Finally, Ding, et al. [26] recently reported that repetitive treatments of giant size AVMs with SRS yielded poorer obliteration outcomes of 67%, 36%, and 73% at zero, three, and 10 years respectively and worse SAEs. By contrast, single SRS treatment generated better obliteration rates of 79%, 53%, and 84% over the same time course with less SAEs (Table 4).
Obliteration rate increased with combined Embo/SRS treatment

| Authors                      | N  | SM Grade | % Obliteration SRS | Embo | % Hemorrhage | % P-ND | % Mortality |
|------------------------------|----|----------|--------------------|------|--------------|--------|-------------|
| Beltramello et al. (2005)    | 113| I-11 III-V| NR >50** | ND   | ND           | 28.6^  | NR          | 0            |
| Daylai et al. (2014)         | 95 | III-V    | 40     | 0    | 45*, 56**,63*** | 8      | 5           | 0            |
| Ding et al. (2013)           | 148| III-V    | NR     | 0    | 68***        | 1.6    | 2           | 0            |
| Pierot et al. (2013)         | 20 | I-II III-IV| NR     | 58** | 71.4** NR NR | 0      | 10          | 0            |
| Pollock et al. (1996 b)      | 34 | IV-V     | NR     | NR   | 65**         | 2.4    | 0           | 0            |
| Gobin et al. (1996)          | 125| II-VI    | NR     | NR   | 65*          | 3      | 0           | 1.6          |
| Blackburn et al. (2011)      | 21 | IV-V     | NR     | NR   | 81*          | 0      | 0           | 0            |
| Han et al. (2013)            | 28 | I-II III-IV| 100**  | 73** | ND           | ND     | ND          | NR           |
| Zabel–du Bois et al. (2007)  | 50 | II-1V    | ND     | ND   | 67*, 78**    | 2.2    | NR          | 0            |

Obliteration rate was worse with combined Embo/SRS or repeated SRS treatment

| Authors                      | N  | SM Grade | % Obliteration SRS | Embo | % Hemorrhage | % P-ND | % Mortality |
|------------------------------|----|----------|--------------------|------|--------------|--------|-------------|
| Kano et al. (2012)           | 120| I-VI     | ND     | ND   | 35*, 55**, 59*** | 2.7    | 2.5         | 5.8          |
| Sirin et al. (2006)          | 28 | IV-VI    | ND     | ND   | 21-29*       | 2.7    | 5-14        | 7            |
| Koga et al. (2011)           | 44 | II-IV    | ND     | ND   | 52**         | 2.4    | 5           | 12           |
| Xu et al. (2014)             | 1988| II-VI | 59'    | NR   | 41*          | 7.3    | 3.3         | 0            |
| Ding et al. (2016)           | 554| IV-V     | S=79*, 53*74**, 84*** | R=67*, 36*, 57**, 73*** | 3.8 (m) 10 (m) | 7 (m) | 13 (m) | 1.2 1.2   |

Obliteration rate did not change significantly with combined Embo/SRS treatment

| Authors                      | N  | SM Grade | % Obliteration SRS | Embo | % Hemorrhage | % P-ND | % Mortality |
|------------------------------|----|----------|--------------------|------|--------------|--------|-------------|
| Wang et al. (2014)           | 116| IV-VI    | 82**              | NR   | 82**         | 1.9    | 0.8         | 0            |
| Sousa et al. (2016)          | 59 | III-V    | 95'(Es)           | ND   | ND           | 2.2    | 6.7         | 0            |
| Karlsson et al (2007)        | 133| III-IV   | 62                | ND   | ND           | 7      | 7           | 0            |
| Maruyama et al. (2005)       | 32 | II-V     | 64*, 72**ND       | ND   | 0            | 3      | 0           |              |

TABLE 4: (N) Number of patients, (*0-1 yr,*1-3 yrs; **4-6 yrs; ***7-10 yrs), follow-up periods, (NR) Not recorded, (ND) Not determined, (P-ND) Permanent neurological deficits, (S) Values for single SRS, (R) Values for repeated SRS, (m) Mean, (Es) Estimated from the angiographies.

This finding provided awareness that successive SRS treatment of giant size AVMs is not an ideal strategy for treatment, in particular, if they localize in eloquent brain regions and accounts for the reason why the need of good embo materials is crucial for the reduction of large nidus sizes prior to SRS.

It is possible to combine embolization and SRS in AVM treatment without appreciable change in outcome

Wang, et al. in 2014 [35] used the same approach on patient groups (SM 1-II, SMIII-IV, SM V-VI) and treatment techniques and showed remarkable percent obliteration score (81.9%) for both SRS alone or combined embo/SRS treatments in 116 patients with minimal SAEs. Sousa, et al. [36] gathered similar trend of results. Although their data did not quantitate the obliteration rates, deductions made from the angiography are that of complete obliteration occurred with both types of treatments. Additionally, Karlsson, et al. [18], Sousa, et al. [36] and Maruyama, et al. [40] obtained reasonably high obliteration rates.
between 64%-72% with large AVMs after SRS alone treatments (Table 4). Further, Mortazavi, et al. [41] carried out parallel studies in 2013 using the similar techniques and methods and showed no significant difference in obliteration outcomes and adverse events over three-year follow-up period with combined treatments. Finally, Henkes, et al. in 1998 [42] reported complications such as persistent venous stagnation and intranidal aneurysm encountered in combined embolization and SRS therapy and arrived at a conclusion that it is rare to achieve an overall fruitful outcome with combined treatments.

**Plausible factors account for setbacks in AVM treatment outcomes**

This review sought to use different case-oriented studies to show data from single as well as combined AVM treatment outcomes and how these results had been very diverse. A particular view of the literature has revealed several reasons why inconsistencies in outcomes reported by different groups should not be surprising. We determined significant bias introduction into the various studies from different clinical settings, which we have indicated below as crucial factors that require consideration when planning AVM surgery:

1) AVM size and complexity determines the aggressiveness of treatment [9,14,17]. Therefore, it is important to have the precise measurement of sizes; size should also be a critical determinant of grouping patients for treatment to minimize variations in outcome.

2) AVM drainage into the deep venous system is a crucial determinant of neurological deficits; therefore, it is important to aim at preventing disruption of the AVM surroundings, as this can impair drainage and cause frequent hemorrhage [9,16].

3) The nature of adjuvant used in embolization is essential, as the liquid types, such as polyvinyl alcohol (PVA) and nBCA are leaky and can cause distal catheter gluing during surgery [17,29]. In fact, studies have revealed that embol complications can be quite dramatic; accounting for over 10% morbidity and mortality rates [27,42]. The use of Onyx, a copolymer, however, has an advantage of precipitating blood upon contact, avoiding gluing and thus has become a more favorable embolizing material [43-44]. Additionally, Onyx can occlude large portions of the nidus through series of injections to prevent hemorrhage and will reduce the AVM size by at least 50% for accessibility and safety during SRS [45].

4) Staging the dosage of an embolization material per subgroup is an important determinant for an effective therapy and requires careful calculation. Under dosage will not work efficaciously and ultimately results in a reduction in obliteration rates; and over dosage can cause SAEs such as speech and vision impairment, partial paralysis, seizures and even increased mortality rates [2,28].

5) The depth and cerebral localization of the AVM is an important determinant of treatment strategy. If an AVM is in the non-eloquent region of the brain and not deeply embedded, the catheter can reach the nidus for both embolization and SRS procedures to a favorable treatment outcome. A giant AVM in the deep eloquent region, however, will either, a) presents itself as embolization and SRS resistant spot, or b) an attempt to treat it could result in a deleterious adverse event (AE) such as increased intracranial hemorrhage, loss of speech, vision, and stroke [2,36]. For AVMs in such obscure and sensitive regions, there is the need to use much thinner catheters and microwires to be able to direct them into the nidus, and also a careful balance between health and risk decision need to be made about radioactive dosage to make the combined treatment much safer and feasible.

6) After performing embolization, recanalization of the nidus can occur in such a way that the blood vessel lumen of the occluded feeders to the nidus is restored spontaneously [29] and it can bring about re-expansion and change in its configuration, thereby, limiting access to the SRS procedure.

7) Liquid embolization materials such as nBCA and ethylene-vinyl alcohol copolymer (EVOH) can cause beam attenuation during GSK procedures such that the radiation dose (the number of kilovoltage radiation photons) reduces in an embolized nidus [46-47]. Onyx, which has been shown to have profound embolization advantages [17,44-45], unfortunately, was reported in a few studies that it could also cause a reduction in beam dosage [17,46-48]. Consequently, this can reduce obliteration rates and have a negative impact on outcomes. Fortunately, if such technical limitation is observable at initial treatment stages, adjustments could be made for a patient to overcome the effect. It is wise to increase the radiation dosage performed by employing a high-powered (60) Co beam with higher radiation strength [47].

8) Aneurysms are present in the arteries feeding the nidus and can rupture because of their delicate nature and cause bleeding in the AVM region [49]. SRS procedure can delay because the neurosurgeon has to use a microscope to isolate the blood vessel that feeds an aneurysm and halt its blood supply to enable the SRS procedure performed. Consequently, this can bring about hemorrhagic stroke.

9) Individuals diagnosed with AVM are at risk of suffering from intracranial hemorrhage, seizures, vascular diseases, neurological deficits, and stroke making it difficult for drastic surgery decisions for them. Therefore, pre-existence of any of these conditions prior to AVM diagnosis could result in higher risk of...
Conclusions
Our analysis set to determine reasons for inconsistencies in AVM combined embolization and SRS treatment outcomes. Certainly in a cohort study, if a subset of patients in a group encounters any of these nine setbacks mentioned above, it will influence a cumulative outcome. Our analysis clearly provides an awareness that the reported varying outcomes in the treatment of patients bearing giant size AVMs might be due to lack of blending all of these crucial factors when planning individuals’ customized treatments. Recent advances in endovascular techniques and discovery of better embolizing adjuvants should aid in minimizing these contradictory reports and bring about more reliable, efficient and safer operations.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to express our inmost appreciation to Dr. Susanna Dodgson, Director of the Medical Writing Institute, for being a diligent mentor and for her incredible guidance in the preparation of this manuscript.

References

1. Kim H, Su H, Weinsheimer S, et al.: Brain arteriovenous malformation pathogenesis: A response-to-injury paradigm. Acta Neurochir. 2011, 111:85–92. 10.1007/978-3-7091-0693-5_14
2. Ondra SL, Troup H, George ED, et al.: The natural history of symptomatic arteriovenous malformations of the brain: A 24-year follow-up assessment. J Neurosurg. 1990, 75:387–391.
3. Stapf C, Khaw AV, Sciaccia RR, et al.: Effect of age on clinical and morphological characteristics in patients with brain arteriovenous malformation. Stroke. 2003, 34:2664–2669. 10.1161/01.STR.0000094824.03572.98
4. American Heart Association. (2012). Accessed: 10/25/2012: http://www.strokeassociation.org/STROKEORG/AboutStroke/TypesofStroke/HemorrhagicBleeds/What-Is-an-Arteriovenous-Malfor...
5. Thomas MJ, Surendran S, Abraham M, et al.: Genetic and epigenetic mechanisms in the development of arteriovenous malformations in the brain. Clin Epigenetics. 2016, 8:1–8. 10.1186/s13148-016-0248-8
6. Parsa AT, Solomon RA: Vascular malformations affecting the nervous system. Principles of Neurosurgery. Rengachary S, Ellenbogen G, (ed): Elsevier Mosby, Edinburgh, New York; 2005. 15:1–18.
7. Koltz MT, Polifka AJ, Saloto A, et al.: Long-term outcome of gamma knife stereotactic radiosurgery for arteriovenous malformations graded by the Spetzler–Martin classification. J Neurosurg. 2015, 118:74–83. 10.3171/2012.9.JNS113239
8. Berman MF, Sciaccia RR, Pile-Spellman J, et al.: The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000, 47:388–96.
9. Stapf C, Mast H, Sciaccia RR, et al.: Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006, 66:1350–55. 10.1212/01.wnl.0000210524.68507.87
10. Koenigsberg RA: Brain imaging in arteriovenous malformation. Medscape J Med. 2017, 1–18. Accessed: 3/2/2017: http://emedicine.medscape.com/article/337220-overview#a4.
11. Tsuchiya K, Kato S, Yoshino A, et al.: MR digital subtraction angiography of cerebral arteriovenous malformations. AJNR Am J Neuroradiol. 2000, 21:707–711.
12. Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. J Neurosurg. 2008, 108:186–193. 10.3171/2008.108/007186
13. Barr JC, Ogihyi CS: Selection of treatment modalities or observation of arteriovenous malformations. Neurosurg Clin N Am. 2012, 23:63–75.
14. Dalayi R, Thoefanis T, Starke R M, et al: Stereotactic radiosurgery with neoadjuvant embolization of larger arteriovenous malformations: An institutional experience. Biomed Res Int. 2014, 2014:1–8. 10.1155/2014/506518
15. Ding D, Chun-Po Yen, Xu Z, et al.: Radiosurgery for patients with unruptured intracranial arteriovenous malformations. J Neurosurg. 2015, 118:958–966. 10.3171/2015.2.JNS15239
16. Hermsenemi JAI, Dashil R, Jevula S, et al.: Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008, 63:825–9. 10.1227/01.NEU.0000356041.82582.5E
17. Pierot L, Kadiouka K, Litre F, et al.: Combined treatment of brain AVMs with the use of Onyx embolization followed by radiosurgery. AJNR Am J Neuroradiol. 2013, 34:1955–1400. 10.3174/ajnr.A5409
18. Karlsson B, Jokura H, Yamamoto M, et al.: Is repeated radiosurgery an alternative to staged radiosurgery for very large brain arteriovenous malformations? J Neurosurg. 2007, 107:740–744. 10.3171/2007.2.0740
19. Lee C-C, Chen C-J, Ball B, et al.: Stereotactic radiosurgery for arteriovenous malformations after Onyx embolization: a case-control study. Journal of Neurosurg. 2015, 125:126–135. 10.5271/jnee.2015.125.126

20. Pollock BE, Lumsford LD, Konidriolia D, et al.: Stereotactic radiosurgery for post-gene lute visual pathway arteriovenous malformations. J Neurosurg. 1996, 84:347–341. 10.5271/jnee.1996.84.5.347

21. Pollock B E, Gorman DA, Coffey RJ: Patient outcomes after arteriovenous malformation radiosurgical management: Results based on a 5- to 14-year follow-up study. Neurosurgery. 2003, 52:1291–1297. 10.1227/01.NEU.0000064800.26214.FE

22. Söderman M1, Karlsson B, Launnay L, et al.: Volume measurement of cerebral arteriovenous malformations from angiography. Neuroradiology. 2000, 42:697–702. 10.1007/s002340000057

23. Chang S D, Marcellus M L, Marx M P, et al.: Multimodality treatment of giant intracranial arteriovenous malformations. Neurosurgery. 2007, 61:432–442. 10.5271/jnee.61.61.432

24. Reinard KA, Papaney AH, Basheer AHA, et al.: Surgical management of giant intracranial arteriovenous malformations: A single center experience over 32 years. Neurosurgery. 2015, 84:1765–1778. 10.1016/j.wneu.2015.07.051

25. Gobin YP, Laurent A, Merienne L, et al.: Treatment of brain arteriovenous malformations by embolization and radiosurgery. Journal of Neurosurg. 1996, 85:19–28.

26. Ding D, Xu Z, Shih HH, et al.: P56 worse stereotactic radiosurgery outcomes for intracranial arteriovenous malformations after repeat vs initial treatment: A matched cohort study. Neurosurgery. 2016, 63:187–188.

27. van Rooij WJ, Sluzewski M, Beute GN, et al.: Brain AVM embolization with Onyx. Am J Neuroradiol. 2007, 28:172–178.

28. Plasencia AR, Santillan A: Embolization and radiosurgery for arteriovenous malformations. Surg Neurol Int. 2012, 2:90–104.

29. Beltramello A, Zampieri P, Ricciardi G, et al.: Combined treatment of brain AVMs: Analysis of five years (2000-2004) in the Verona experience. Interv Neuroradiol. 2005, 11:63–72. 10.1177/159101990501105111

30. Koga T, Shin M, Terahara A, et al.: Outcomes of radiosurgery for brainstem arteriovenous malformations. Neurosurgery. 2011, 69:45–51.

31. Blackburn SL, Ashley WW Jr, Rich KM, et al.: Combined endovascular embolization and stereotactic radiosurgery in the treatment of large arteriovenous malformations. J Neurosurg. 2011, 114:1758–67. 10.5271/jnee.2011.114.1758

32. Hans H, Kim DG: Stereotactic radiosurgery for brainstem cavernous malformations. World Neurosurg. 2013, 80:187–189. 10.1016/j.wneu.2012.11.022

33. Zabel–du Bois A, Milker-Zabel S, Huber P, et al.: Risk of hemorrhage and obliteration rates of linac-based radiosurgery for cerebral arteriovenous malformations treated after partial embolization. Radiat Oncol. 2007, 68:999–1003. 10.1016/j.ijrobp.2007.01.027

34. Xu F, Zhong J, Ray A, et al.: Stereotactic radiosurgery with and without embolization for intracranial arteriovenous malformations: a systematic review and meta-analysis. Neurorad Focus. 2014, 57:16. 10.1016/j.foc.us.2014.6

35. Wang YC, Huang YC, Chen HC, et al.: Linear accelerator stereotactic radiosurgery in the management of intracranial arteriovenous malformations: long-term outcome. Cerebrovasc Dis. 2014, 37:342–349. 10.1159/000360756

36. Sousa EC, Teixeira MJ, Piske RL, et al.: The role of preradiosurgical embolization in the management of grades III, IV, and V. Front. Surg. 2016, 3:57. 10.3389/fsurg.2016.00057

37. Kano H, Konidriolia D, Flickinger JG, et al.: Stereotactic radiosurgery for arteriovenous malformations, Part 3: Outcome predictors and risks after repeat radiosurgery. J Neurosurg. 2012, 116:21–32. 10.5271/jnee.2012.116.21

38. Sirin S, Konidriolia D, Niranjan A, et al.: Prospective staged volume radiosurgery for large arteriovenous malformations: indications and outcomes in otherwise untreated patients. Neurosurgery. 2006, 58:17–27.

39. Lee CC, Chen CJ, Ball B, et al.: Stereotactic radiosurgery for arteriovenous malformations after Onyx embolization: a case-control study. J Neurosurg. 2015, 123:126–135. 10.5271/jnee.2015.123.126

40. Maruyama K, Shin M, Tago M, et al.: Gamma knife surgery for arteriovenous malformations involving the corpus callosum. J Neurosurg. 2005, 102:49–52.

41. Mortazavi MM, Patel D, Griesenauer CJ, et al.: Long-term control of large pontine arteriovenous malformation using gamma knife therapy: a review with the illustrative case. Brain Behav. 2013, 3:329–334. 10.1002/brb3.149

42. Henkes H, Naher HC, Berg-Dammer E, et al.: Endovascular therapy of brain AVMs prior to radiosurgery. Neurol Res. 1998, 20:479–492. 10.1080/01616412.1998.11740552

43. Mounayer C, Hammani N, Piotin M, et al.: Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients. AJNR Am J Neuroradiol. 2007, 28:518–523.

44. Hamada I, Kai Y, Morioka M, et al.: A mixture of ethylene vinyl alcohol copolymer and ethanol yielding a non-adhesive liquid embolic agent to treat cerebral arteriovenous malformations: initial clinical experience. J Neurosurg. 2002, 97:881–8. 10.5271/jnee.2002.97.4.881

45. Choi JH, Mohr JP: Brain arteriovenous malformations in adults. Lancet Neurol. 2005, 4:299–308. 10.1016/S1474-4422(05)70727-9

46. Mamalui-Hunter M, Jiang T, Rich KM, et al.: Effect of liquid embolic agents on Gamma Knife surgery dosimetry for arteriovenous malformations. Clinical article. J Neurosurg. 2011, 115:364–370. 10.5271/jnee.2011.115.364

47. Shtrasn S, Schffer D, Corn BW, et al.: Radiosurgical treatment planning of AVM the following embolization with Onyx: possible dosage error in treatment planning can be averted. J Neurorad. 2010, 98:271–276. 10.1073/j.neurooncology.a.2010.11.017

48. Andrade-Souza YM, Ramani M, Scora D, et al.: Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery. 2007, 60:445–452. 10.1227/01.NEU.0000255347.25959.D0

49. Li LR, Young C, Chaudhary B: Intraoperative mild hypothermia for postoperative neurological deficits in people with an intracranial aneurysm. Cochrane Lib. 2016, 3:10.1002/14651858.CD008445.pub3
50. Jiang R1, Gong SG, Pudasaini B, et al.: Diffuse pulmonary arteriovenous fistulas with pulmonary arterial hypertension: Case report and review. Medicine. 2016, 95:3177.